Peter L. Collins

38.9k total citations · 1 hit paper
392 papers, 23.5k citations indexed

About

Peter L. Collins is a scholar working on Epidemiology, Infectious Diseases and Animal Science and Zoology. According to data from OpenAlex, Peter L. Collins has authored 392 papers receiving a total of 23.5k indexed citations (citations by other indexed papers that have themselves been cited), including 347 papers in Epidemiology, 166 papers in Infectious Diseases and 64 papers in Animal Science and Zoology. Recurrent topics in Peter L. Collins's work include Respiratory viral infections research (288 papers), Virology and Viral Diseases (165 papers) and Viral Infections and Vectors (85 papers). Peter L. Collins is often cited by papers focused on Respiratory viral infections research (288 papers), Virology and Viral Diseases (165 papers) and Viral Infections and Vectors (85 papers). Peter L. Collins collaborates with scholars based in United States, United Kingdom and Germany. Peter L. Collins's co-authors include Brian R. Murphy, Alexander Bukreyev, Ursula J. Buchholz, Mark E. Peeples, Barney S. Graham, Mario H. Skiadopoulos, Rachel Fearns, Michael N. Teng, Gail W. Wertz and Siba K. Samal and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Peter L. Collins

389 papers receiving 22.7k citations

Hit Papers

Sorafenib in combination with transarterial chemoembolisa... 2017 2026 2020 2023 2017 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial
    2017 331 citations Peter L. Collins et al. profile →

Peers

Peter L. Collins
Barney S. Graham United States
James E. Crowe United States
Guy Boivin Canada
Richard J. Webby United States
Jason S. McLellan United States
Kanta Subbarao United States
Patrick S. Moore United States
Georg Herrler Germany
Richard W. Compans United States
Robert H. Purcell United States
Barney S. Graham United States
Peter L. Collins
Citations per year, relative to Peter L. Collins Peter L. Collins (= 1×) peers Barney S. Graham

Countries citing papers authored by Peter L. Collins

Since Specialization
Citations

This map shows the geographic impact of Peter L. Collins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter L. Collins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter L. Collins more than expected).

Fields of papers citing papers by Peter L. Collins

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter L. Collins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter L. Collins. The network helps show where Peter L. Collins may publish in the future.

Co-authorship network of co-authors of Peter L. Collins

This figure shows the co-authorship network connecting the top 25 collaborators of Peter L. Collins. A scholar is included among the top collaborators of Peter L. Collins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter L. Collins. Peter L. Collins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Akhtar, Muzamil, et al.. (2025). Trends and Disparities in Acute Myocardial Infarction and Type 2 Diabetes Mellitus-Related Mortality in the United States from 1999-2022. Nutrition Metabolism and Cardiovascular Diseases. 35(9). 104063–104063. 2 indexed citations
2.
3.
Liu, Alexander, Raheel Ahmed, Kamleshun Ramphul, et al.. (2024). Outcomes of Cardiac Resynchronization Therapy (CRT) in Cardiac Sarcoidosis Patients with a Range of Ejection Fractions. ESC Heart Failure. 12(1). 592–602. 6 indexed citations
4.
Saul, Sirle, Jin Dai, Sonja R. Surman, et al.. (2024). Human parainfluenza virus 3 vaccine candidates attenuated by codon-pair deoptimization are immunogenic and protective in hamsters. Proceedings of the National Academy of Sciences. 121(25). e2316376121–e2316376121. 2 indexed citations
5.
Ahmed, Raheel, Mushood Ahmed, Peter L. Collins, et al.. (2024). Nationwide Cross-Sectional Analysis of Mortality Trends in Patients with Sarcoidosis and Non-Ischemic Cardiovascular Disease—The Impact of Gender, Ethnicity, Geographical Location, and COVID-19 Pandemic. Journal of Clinical Medicine. 13(23). 7463–7463. 7 indexed citations
6.
Karron, Ruth A., Kimberli Wanionek, Alexander C. Schmidt, et al.. (2023). Evaluation of a Live-Attenuated Human Parainfluenza Virus Type 2 Vaccine in Adults and Children. Journal of the Pediatric Infectious Diseases Society. 12(3). 173–176. 3 indexed citations
7.
Karron, Ruth A., Cindy Luongo, Suzanne Woods, et al.. (2023). Evaluation of the Live-Attenuated Intranasal Respiratory Syncytial Virus (RSV) Vaccine RSV/6120/ΔNS2/1030s in RSV-Seronegative Young Children. The Journal of Infectious Diseases. 229(2). 346–354. 21 indexed citations
8.
Karron, Ruth A., Jessica E. Atwell, Elizabeth J. McFarland, et al.. (2020). Live-Attenuated Vaccines Prevent Respiratory Syncytial Virus–associated Illness in Young Children. American Journal of Respiratory and Critical Care Medicine. 203(5). 594–603. 42 indexed citations
9.
Massey, Philip, Thomas A. Bida, Peter L. Collins, et al.. (2013). As Big and As Good As It Gets: The Large Monolithic Imager for Lowell Observatory's 4.3-m Discovery Channel Telescope. 221. 2 indexed citations
10.
Dunham, Edward W., Thomas A. Bida, A. S. Bosh, et al.. (2012). First Stellar Occultation Observation with SOFIA. AAS. 219. 1 indexed citations
11.
Collins, Peter L., et al.. (2011). A Respiratory Syncytial Virus Replicon That Is Noncytotoxic and Capable of Long-Term Foreign Gene Expression. Journal of Virology. 85(10). 4792–4801. 23 indexed citations
12.
Chaiwatpongsakorn, Supranee, Richard M. Epand, Peter L. Collins, & Mark E. Peeples. (2011). Soluble Respiratory Syncytial Virus Fusion Protein in the Fully Cleaved, Pretriggered State Is Triggered by Exposure to Low-Molarity Buffer. Journal of Virology. 85(8). 3968–3977. 56 indexed citations
13.
Jessen, Birthe, et al.. (2007). Influence of a Single Viral Epitope on T Cell Response and Disease After Infection of Mice with Respiratory Syncytial Virus. The Journal of Immunology. 179(12). 8264–8273. 14 indexed citations
14.
15.
Zhang, Liqun, Alexander Bukreyev, Catherine Thompson, et al.. (2004). Infection of Ciliated Cells by Human Parainfluenza Virus Type 3 in an In Vitro Model of Human Airway Epithelium. Journal of Virology. 79(2). 1113–1124. 238 indexed citations
16.
Bukreyev, Alexander, Mario H. Skiadopoulos, Josephine M. McAuliffe, et al.. (2002). More antibody with less antigen: Can immunogenicity of attenuated live virus vaccines be improved?. Proceedings of the National Academy of Sciences. 99(26). 16987–16991. 11 indexed citations
17.
Murphy, Brian R. & Peter L. Collins. (2002). Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. Journal of Clinical Investigation. 110(1). 21–27. 4 indexed citations
18.
Murphy, Brian R. & Peter L. Collins. (2002). Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. Journal of Clinical Investigation. 110(1). 21–27. 51 indexed citations
19.
Hallak, Louay K., Peter L. Collins, Warren Knudson, & Mark E. Peeples. (2000). Iduronic Acid-Containing Glycosaminoglycans on Target Cells Are Required for Efficient Respiratory Syncytial Virus Infection. Virology. 271(2). 264–275. 194 indexed citations
20.
Collins, Peter L., Alexander Bukreyev, Rachel Fearns, et al.. (1999). Rational Design of Live-Attenuated Recombinant Vaccine Virus for Human Respiratory Syncytial Virus by Reverse Genetics. Advances in virus research. 54. 423–451. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Barney S. Graham Breakdown of academic impact, for papers by James E. Crowe Breakdown of academic impact, for papers by Guy Boivin Breakdown of academic impact, for papers by Richard J. Webby Breakdown of academic impact, for papers by Jason S. McLellan Breakdown of academic impact, for papers by Kanta Subbarao Breakdown of academic impact, for papers by Patrick S. Moore Breakdown of academic impact, for papers by Georg Herrler Breakdown of academic impact, for papers by Richard W. Compans Breakdown of academic impact, for papers by Robert H. Purcell
Rankless by CCL
2026